Intralesional PV-10 Treatment Leads to the Induction of Anti-Tumor Immunity

Moffitt Cancer Center Poster Presentation March 23 and 24, 2012

Results Detailed at the Society of Surgical Oncology Annual Meeting

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Mar 26, 2012 - Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that nonclinical data on the immunologic mechanism of action of PV-10, presented at the 2012 Society of Surgical Oncology Annual Meeting, confirms that PV-10 chemoablation of melanoma lesions leads to a systemic response and the induction of systemic anti-tumor immunity. The poster presentation is available via the link below.

http://www.pvct.com/publications/Paul-Toomey-PV10-SSO-2012.pdf

The study was undertaken to elucidate the apparent systemic effect of PV-10 that has been observed in Phase 1 and Phase 2 clinical trials of PV-10, leading to regression of untreated bystander lesions in some melanoma patients. The report of the nonclinical mechanism study's findings, entitled “Intralesional Injection of Melanoma with Rose Bengal Induces Regression of Untreated Synchronous Melanoma in a Murine Model,” was authored by P. Toomey, K. Kodumudi, L. Martin, A. Mackay, A. Sarnaik and S. Pilon-Thomas of the Moffitt Cancer Center. The abstract, #P265, was included in the Society of Surgical Oncology's 65th Annual Symposium Abstract Book and was published in Annals of Surgical Oncology, 2012; 19(1): S125. Detailed experimental data was presented during the Annual Meeting's melanoma poster session on March 23 and 24, 2012. In particular, an immune-mediated anti-tumor response to PV-10 treatment was observed, including induction of tumor-specific interferon-gamma production by splenocytes derived after PV-10 treatment compared to control.

Paul Toomey, M.D., of the Moffitt Cancer Center and University of South Florida, College of Medicine, Tampa, FL, presented the poster on behalf of his colleagues. Dr. Toomey said, “Our data confirms that intratumoral PV-10 causes both a direct anti-tumoral response of the injected tumor and a systemic tumor-specific activation of the immune system. As we continue to probe this very interesting process, we look forward to presenting further data from our ongoing research of this unique agent in both nonclinical and clinical studies.”

Craig Dees, Ph.D., CEO of Provectus said, “We are delighted to see confirmation of the anti-tumor immunologic processes stimulated by PV-10 chemoablation and the exciting discoveries of Dr. Toomey and his colleagues that are provided in the poster presentation. We very much look forward to even more detailed data from the Moffitt team of researchers.”

About the Society of Surgical Oncology®

The Society of Surgical Oncology is the premier organization for surgeons and health care providers dedicated to advancing and promoting the science and treatment of cancer. The Society's focus on all solid-tumor disease sites is reflected in its Annual Cancer Symposium, monthly scientific journal (Annals of Surgical Oncology), special initiatives, and committee structure. For more information on the Annual Meeting, please go to: http://www.surgonc.org/meetings--events/annual-cancer-symposium.aspx

About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

Contact: Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, CFO, COO
866-594-5999, ext. 30
or
Porter, LeVay & Rose, Inc.
Marlon Nurse, DM, VP – Investor Relations
Bill Gordon, SVP – Media Relations
212-564-4700

 

Posted: March 2012

View comments

Hide
(web4)